NOVODX Corporation a leader in next-generation at-home and point-of-care at home lab-testing, announced that six-time NBA All-Star and entrepreneur Amar’e Stoudemire has joined its Advisory Board. Stoudemire will lend his influence, network, and passion for wellness to help accelerate NOVODX’s mission of making reliable, affordable preventive healthcare at home testing available to everyone.
Health Technology Insights: Corewell, Quest Partner to Expand Lab Services in Michigan
At the center of NOVODX’s innovation is the GoldN Reader, a portable at home testing platform. The GoldN Reader is being designed to provide rapid, on-site results in under 15 minutes, with the goal of eliminating the need to ship samples to a laboratory. The platform is intended to support a broad menu of tests, including women’s health, fertility, infectious diseases, oncology, micronutrient analysis, and preventive screenings. By enabling access to timely information, the GoldN Reader aims to help bridge the gap between early detection and action, assisting in better outcomes.
“Access to reliable, timely health information changes lives,” said Amar’e Stoudemire. “I’m proud to join NOVODX in bringing powerful tools like the GoldN Reader into communities everywhere, so people can take control of their health before problems become critical.”
Stoudemire, known for his standout NBA career with the Phoenix Suns, New York Knicks, and Miami Heat, has built a diverse business portfolio spanning sports, wellness, and philanthropy. His commitment to holistic health aligns with NOVODX’s focus on empowering individuals and communities to proactively manage their well-being.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 26 August 2025
“Amar’e Stoudemire’s leadership, vision, and personal dedication to health makes him an invaluable voice on our Advisory Board,” said Nancy Torres, CEO of NOVODX. “We share a belief that healthcare should be equitable, convenient, and informed; and that innovation should serve people, not the other way around.”
NOVODX is currently expanding the GoldN Reader’s test menu and preparing for market Launch Q1 of 2026, with the goal of transforming the way healthcare data for informed decisions is delivered and accessed.
Health Technology Insights: Leal Therapeutics Raises $30Million for Neuro-Metabolic Therapies
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
